Cardiol Therapeutics Inc. (NASDAQ:CRDL) Given Consensus Recommendation of "Buy" by Analysts

Cardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) has been given a consensus rating of "Buy" by the seven analysts that are currently covering the company, Marketbeat.com reports. Five investment analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $8.40.

Several analysts have commented on CRDL shares. HC Wainwright reiterated a "buy" rating and set a $9.00 target price on shares of Cardiol Therapeutics in a research note on Monday. Rodman & Renshaw assumed coverage on Cardiol Therapeutics in a research report on Tuesday, January 28th. They set a "buy" rating and a $7.00 price objective on the stock. Finally, RODMAN&RENSHAW raised Cardiol Therapeutics to a "strong-buy" rating in a research report on Tuesday, January 28th.

Institutional Trading of Cardiol Therapeutics

Several large investors have recently modified their holdings of CRDL. Jones Financial Companies Lllp purchased a new position in Cardiol Therapeutics in the fourth quarter worth about $25,000. Townsquare Capital LLC bought a new position in shares of Cardiol Therapeutics in the 3rd quarter worth approximately $27,000. Wealth Enhancement Advisory Services LLC purchased a new position in shares of Cardiol Therapeutics in the third quarter worth approximately $27,000. Jane Street Group LLC bought a new stake in Cardiol Therapeutics during the third quarter valued at approximately $29,000. Finally, Cetera Investment Advisers bought a new stake in Cardiol Therapeutics during the fourth quarter valued at approximately $56,000. Institutional investors own 12.49% of the company's stock.

Remove Ads

Cardiol Therapeutics Stock Down 5.6 %

Shares of NASDAQ:CRDL traded down $0.07 during trading on Friday, reaching $1.11. 275,596 shares of the stock traded hands, compared to its average volume of 268,816. The stock has a market cap of $91.28 million, a P/E ratio of -2.81 and a beta of 0.91. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.49 and a current ratio of 2.49. The stock has a 50-day moving average of $1.31 and a two-hundred day moving average of $1.68. Cardiol Therapeutics has a 52-week low of $1.06 and a 52-week high of $3.12.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.